Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Nov 26:9:179.
doi: 10.1186/s13023-014-0179-4.

Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management

Shuke Nie  1 , Guiqin Chen  2 , Xuebing Cao  3 , Yunjian Zhang  4
Affiliations
Review

Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management

Shuke Nie et al. Orphanet J Rare Dis. .

Abstract

Cerebrotendinous xanthomatosis (CTX) OMIM#213700 is a rare autosomal-recessive lipid storage disease caused by mutations in the CYP27A1 gene; this gene codes for the mitochondrial enzyme sterol 27-hydroxylase, which is involved in bile acid synthesis. The CYP27A1 gene is located on chromosome 2q33-qter and contains nine exons. A CYP27A1 mutation leads to decreased synthesis of bile acid, excess production of cholestanol, and consequent accumulation of cholestanol in tissues. Currently there is no consensus on the prevalence of CTX, one estimate being <5/100,000 worldwide. The prevalence of CTX due to the CYP27A1 mutation R362C alone is approximately 1/50,000 in Caucasians. Patients with CTX have an average age of 35 years at the time of diagnosis and a diagnostic delay of 16 years. Clinical signs and symptoms include adult-onset progressive neurological dysfunction (i.e., ataxia, dystonia, dementia, epilepsy, psychiatric disorders,peripheral neuropathy, and myopathy) and premature non-neurologic manifestations (i.e., tendon xanthomas, childhood-onset cataracts, infantile-onset diarrhea, premature atherosclerosis, osteoporosis, and respiratory insufficiency). Juvenile cataracts, progressive neurologic dysfunction, and mild pulmonary insufficiency are unique symptoms that distinguish CTX from other lipid storage disorders including familial dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and sitosterolemia, all of which might also present with xanthomas and cardiovascular diseases. Brain magnetic resonance imaging (MRI) shows bilateral lesions in the dentate nucleus of the cerebellum and mild white matter lesions. The classical symptoms and signs, namely elevated levels of cholestanol and bile alcohols in serum and urine, brain MRI, and the mutation in the CYP27A1 gene confirm the diagnosis of CTX. Early diagnosis and long-term treatment with chenodeoxycholic acid (750 mg/d) improve neurological symptoms and contribute to a better prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Metabolic pathway involved in cerebrotendinous xanthomatosis (CTX; modified from Chales and Bjorkhem [ 10 , 74 ] ). Due to a mutation in the CYP27A1 gene, cholesterol cannot be converted into bile acids, but is instead converted into cholestanol and bile alcohol. Providing chenodeoxycholic acid exogenously has a negative feedback effect that reduces synthesis of bile acid, thus preventing accumulation of cholestanol.
Figure 2
Figure 2
Positron emission tomography (PET) imaging results in CTX: pulmonary system involvement. PET reveals a cyst with a gas-fluid level (16 × 20 mm, A and B) and a high-density lesion (12 × 14 mm, C) in the lung.
Figure 3
Figure 3
MRI results: brain. Brain MRI shows T1-weighted (A, arrow) and T2-weighted (B, arrow) hyperintensities in the dentate nuclei.
Figure 4
Figure 4
PET imaging results: brain. Remarkable abnormalities are seen in the basal brain metabolic rate in a patient with CTX. PET reveals hypometabolism in cerebral lobes (especially in the frontal and temporal lobes) in sagittal section (A), and in axial section (B).
Figure 5
Figure 5
5 MRI results: tendon. MRI of both ankles. Sagittal long-T1-weighted image (A, arrow) and short-T2-weighted image (B, arrow), and axial long-T1-weighted image (C, arrow) of fusiform thickenings in the Achilles tendons in a patient with CTX.
Figure 6
Figure 6
PET imaging results: tendon. Unusually high radioactivity is found in both Achilles tendons of a patient with CTX. PET shows abnormal soft-tissue thickening in a CT window in coronal section (A) and in axial section (D), and unusually high radioactivity in Achilles tendons and adjacent regions in PET (B and E) and fusion windows (C and F).
Figure 7
Figure 7
Histology: tendon. HE staining of the tendon masses reveals accumulation of xanthoma cells (fine arrows) and dispersed lipid crystal clefts (coarse arrows). A, 100×; B, 200 × .
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem. 1991;266:7779–7783. - PMC - PubMed
    1. Gallus GN, Dotti MT, Federico A. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci. 2006;27:143–149. doi: 10.1007/s10072-006-0618-7. - DOI - PubMed
    1. Bjorkhem I, Hansson M. Cerebrotendinous xanthomatosis: an inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem Biophys Res Commun. 2010;396:46–49. doi: 10.1016/j.bbrc.2010.02.140. - DOI - PubMed
    1. Lorincz MT, Rainier S, Thomas D, Fink JK. Cerebrotendinous xanthomatosis - Possible higher prevalence than previously recognized. Arch Neurol. 2005;62:1459–1463. doi: 10.1001/archneur.62.9.1459. - DOI - PubMed
    1. Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, Pardo J, Arias M, Ares-Luque A, Duarte J, Muniz-Perez S, Sobrido MJ. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol. 2011;18:1203–1211. doi: 10.1111/j.1468-1331.2011.03439.x. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources